In a report released today, Yasmeen Rahimi from Piper Sandler maintained a Buy rating on Gossamer Bio (GOSS – Research Report), with a price ...

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and ...

The Kern County Coroner’s Office has identified a man killed after a crash on Gossamer Grove Boulevard as 22-year-old Luis ...

EDT Gossamer Bio (GOSS) reports Q4 revenue $9.4M, consensus $7.0MLight Up your Portfolio with Spark:Easily identify stocks' risks and ...

SAN DIEGO (AP) — SAN DIEGO (AP) — Gossamer Bio Inc. (GOSS) on Thursday reported a loss of $33 million in its fourth quarter. On a per-share basis, the San Diego-based company said it had a loss of 15 ...

Gossamer Bio (GOSS) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.21 per share a year ago. These figures are ...

Gossamer Bio (NASDAQ:GOSS – Get Free Report) will likely be posting its quarterly earnings results before the market opens on ...

Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and ...

Newsroom is open 24 hours, please reach us by email at [email protected] or by phone Monday through Friday 9-5. You can place DBA (Fictitious Business Name Statement) orders online by clicking on t ...

SAN DIEGO - Gossamer Bio, Inc. (NASDAQ: GOSS) saw its shares climb 5.4% after the biopharmaceutical company reported better-than-expected fourth quarter results and provided updates on its pulmonary ...

Gossamer Bio develops Seralutinib, which is basically an inhaled TKI that targets vascular remodeling, inflammation, and fibrosis. This makes it ideal for treating PAH and PH-ILD. GOSS has so far ...

Register for the Conference here. Submit Questions for any of the presenting com SAN DIEGO, February 03, 2025--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused ...